Lutonix Global SFA Registry
A Prospective, Global Multicenter, Single Arm Real-World Registry Investigating the Clinical Use and Safety of the LUTONIX Drug Coated PTA Dilatation Catheter
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Allgemeines Krankenhaus Wien
-
-
-
-
-
Antwerp, Belgium, 2020
- ZNA Campus Middelheim
-
-
-
-
-
Dijon, France, 21079
- Chu Le Bocage
-
-
-
-
-
Arnsberg, Germany, 59759
- Karolinen Hospital Huesten
-
Muenchen, Germany, 80331
- Diakoniewerk Muenchen
-
Sonneberg, Germany, 96515
- MEDINOS Kliniken Sonneberg
-
Viechtach, Germany, 94234
- Kreiskrankenhaus Viechtach
-
Weiden, Germany, 92637
- Klinikum Weiden
-
-
-
-
-
Patras, Greece, 26504
- University General Hospital of Patras
-
-
-
-
-
Asti, Italy, 14100
- AO Cardinal Massaia
-
San Donato Milanese, Italy, 20097
- IRCCS Policlinico San Donato
-
Sondalo, Italy, 23035
- Azienda Ospedaliera della Valtellina e dalla Valchiavenna
-
Torino, Italy
- AO Ordine Mauriziano
-
-
-
-
-
Bydgoszcz, Poland, 85-168
- Szpital Uniwersytecki nr 2 im. Biziel
-
Poznan, Poland, 61-848
- Szpital Kliniczny Przemienienia Pańskiego
-
Torun, Poland, 87-100
- Voivodship Specialist Hospital
-
-
-
-
-
Barcelona, Spain, 08036
- Hospital Clinico Barcelona
-
-
-
-
-
Aarau, Switzerland, 5001
- Kantonsspital Aarau
-
-
-
-
-
Liverpool, United Kingdom, L7 8XP
- Royal Liverpool
-
London, United Kingdom, SE1 7EH
- St Thomas' Hospital
-
Manchester, United Kingdom, M13 9WL
- Manchester Royal Infirmary
-
Manchester, United Kingdom, M23 9LT
- Wythenshawe Hospital
-
Newcastle upon Tyne, United Kingdom, WE7 7DN
- Freeman Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or non-pregnant female ≥18 years of age;
- Rutherford Clinical Category ≤ 4;
- Patient is willing to provide 5-year informed consent and comply with the required follow up;
- Stenotic or obstructive vascular lesions of the femoropopliteal artery;
- Lesion(s) can be treated with available LUTONIX Drug Coated PTA Dilatation Catheter device size matrix per current IFU;
- At least one patent native outflow artery to the ankle free from significant lesion (≥50% stenosis) as confirmed by angiography (treatment of outflow disease is NOT permitted; treatment of in-flow disease is permitted prior to treatment with the LUTONIX Drug Coated PTA Dilatation Catheter).
Exclusion Criteria:
- Patient is currently participating in an investigational drug or device study;
- Inability to take recommended medications as stated in the IFU or non-controllable allergy to contrast;
- Pregnant or planning on becoming pregnant or men intending to father a child;
- Rutherford Class > 4
- Known inadequate distal outflow or planned future treatment of vascular disease distal to the target lesion
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Lutonix Drug Coated Balloon
Paclitaxel coated ballooncatheter
|
Subject will receive treatment with the Lutonix Drug Coated Balloon
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Freedom from Target Lesion Revascularization (TLR)
Time Frame: 12 months
|
Efficacy: Freedom from TLR at 12 months.
|
12 months
|
|
Freedom from Target Vessel Revascularization(TVR), major index limb amputation, and device- and procedure-related death
Time Frame: 30 days
|
Safety: Freedom at 30 days from TVR, major index limb amputation, and device- and procedure-related death
|
30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CL0004-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.